Shareholder plans sale of 28,335 SLDB shares

A holder of SLDB common stock has filed a notice of proposed sales under Rule 144.

Accepted by SEC EDGAR 02/02/2026 - 08:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

A holder of SLDB common stock has filed a notice of proposed sales under Rule 144. The filing covers 28,335 shares of common stock, to be sold through E*TRADE Financial Corporation on 02/02/2026 on the NASDAQ, with an aggregate market value of $182,389.56. These shares were acquired on the same date through settlement of performance share awards as compensation from the issuer. The filing reports that 82,561,235 shares of this class were outstanding, and indicates no other sales by this holder in the past three months.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for SLDB report?

The Form 144 reports a planned sale of 28,335 shares of SLDB common stock. The shares are to be sold on NASDAQ through E*TRADE Financial Corporation, with an aggregate market value of $182,389.56, as disclosed in the filing.

How many SLDB shares are planned to be sold and at what value?

The filing states that 28,335 SLDB common shares are planned for sale. The disclosed aggregate market value is $182,389.56, indicating the total market value of the shares covered by this specific Rule 144 notice at the time of the filing.

How were the SLDB shares in this Form 144 acquired?

According to the filing, the 28,335 SLDB shares were acquired on 02/02/2026 through settlement of performance shares. The nature of payment is listed as compensation, meaning the securities were received as part of an incentive or award arrangement.

On which exchange will the SLDB shares be sold under this Form 144?

The Form 144 specifies that the SLDB common stock covered by the notice is planned to be sold on the NASDAQ. The broker handling the transaction is listed as E*TRADE Financial Corporation, with its address provided in the filing details.

How many SLDB shares were outstanding when this Form 144 was filed?

The filing reports that 82,561,235 shares of SLDB common stock were outstanding. This figure provides context for the size of the planned 28,335-share sale relative to the total number of shares of this class in existence at that time.

Does the SLDB Form 144 show any other recent sales by this holder?

The section requesting information on securities sold during the past three months contains no disclosed transactions. This indicates that, in this Form 144, the holder did not report other SLDB sales in the three months preceding this notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001997809
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Solid Biosciences Inc.
SEC File Number	001-38360
Address of Issuer	500 Rutherford Avenue Charlestown MASSACHUSETTS 02129
Phone	(617)-337-4680
Name of Person for Whose Account the Securities are To Be Sold	Brooks Gabriel
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	28335	182389.56	82561235	02/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	02/02/2026	Settlement of performance shares	Issuer			28335	02/02/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	The sale reported on this Form 144 was made to cover witholding taxes following the vesting of previously granted performance stock units pursuant to a durable sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-cover-election. The sale does not represent a discretionary trade by Dr. Brooks.
Date of Notice	02/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/15/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)